Kala Pharmaceuticals’s Ocular Disease Program Selected as a Top 10 Project to Watch

WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that its dry eye disease program has been chosen as one of the Top 10 Anti-inflammatory/Autoimmune Projects to Watch by Elsevier Business Intelligence. Guillaume Pfefer, Ph.D., Kala’s President and Chief Executive Officer, will provide a summary of Kala’s ocular disease programs, during his presentation at the 2013 Therapeutic Area Partnerships conference being held November 18-20, 2013 at the Hyatt Regency, Boston. Dr. Pfefer’s presentation will take place at 11:10 a.m. ET on Tuesday, November 19, 2013 during the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch session.

Help employers find you! Check out all the jobs and post your resume.